Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program (American Journal of Clinical Dermatology, (2021), 22, 5, (693-707), 10.1007/s40257-021-00618-3)